[go: up one dir, main page]

MX2014002780A - Composiciones farmaceuticas que comprenden un inhibidor de aromatasa. - Google Patents

Composiciones farmaceuticas que comprenden un inhibidor de aromatasa.

Info

Publication number
MX2014002780A
MX2014002780A MX2014002780A MX2014002780A MX2014002780A MX 2014002780 A MX2014002780 A MX 2014002780A MX 2014002780 A MX2014002780 A MX 2014002780A MX 2014002780 A MX2014002780 A MX 2014002780A MX 2014002780 A MX2014002780 A MX 2014002780A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
aromatase inhibitor
relates
present
bisbenzonitrile
Prior art date
Application number
MX2014002780A
Other languages
English (en)
Other versions
MX360315B (es
Inventor
Ann Taylor
Lloyd B Klickstein
Jeewan Thakur
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014002780(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014002780A publication Critical patent/MX2014002780A/es
Publication of MX360315B publication Critical patent/MX360315B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas de dosis bajas que comprenden el inhibidor de aromatasa 4,4'-[fluoro-(1-H-1,2,4-triazol-1-il)metileno]bisbenzonitrilo, como el ingrediente activo en un portador adecuado. La presente invención también se refiere a un proceso para su preparación y a su uso como medicamentos.
MX2014002780A 2011-09-08 2012-09-06 Composiciones farmaceuticas que comprenden un inhibidor de aromatasa. MX360315B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532459P 2011-09-08 2011-09-08
US201261638588P 2012-04-26 2012-04-26
PCT/US2012/053846 WO2013036563A1 (en) 2011-09-08 2012-09-06 Pharmaceutical compositions comprising an aromatase inhibitor

Publications (2)

Publication Number Publication Date
MX2014002780A true MX2014002780A (es) 2014-06-05
MX360315B MX360315B (es) 2018-10-29

Family

ID=46846026

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014002773A MX343902B (es) 2011-09-08 2012-09-06 Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas.
MX2014002780A MX360315B (es) 2011-09-08 2012-09-06 Composiciones farmaceuticas que comprenden un inhibidor de aromatasa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014002773A MX343902B (es) 2011-09-08 2012-09-06 Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas.

Country Status (31)

Country Link
US (4) US9370505B2 (es)
EP (2) EP2753312B1 (es)
JP (2) JP6280501B2 (es)
KR (3) KR20180030254A (es)
CN (2) CN103781476B (es)
AR (1) AR087790A1 (es)
AU (2) AU2012304694B2 (es)
BR (2) BR112014004879B1 (es)
CA (2) CA2846884C (es)
CL (1) CL2014000552A1 (es)
CY (2) CY1118461T1 (es)
DK (2) DK2753312T3 (es)
ES (2) ES2613667T3 (es)
HR (2) HRP20170002T1 (es)
HU (2) HUE031478T2 (es)
IL (1) IL231234A (es)
IN (1) IN2014DN01619A (es)
LT (2) LT2753313T (es)
MX (2) MX343902B (es)
PE (1) PE20141584A1 (es)
PH (1) PH12014500435A1 (es)
PL (2) PL2753312T3 (es)
PT (2) PT2753313T (es)
RU (2) RU2617510C2 (es)
SG (2) SG2014012132A (es)
SI (2) SI2753312T1 (es)
TN (1) TN2014000059A1 (es)
TW (1) TW201316987A (es)
UY (1) UY34315A (es)
WO (2) WO2013036563A1 (es)
ZA (1) ZA201401040B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2753312T3 (da) * 2011-09-08 2017-02-13 Mereo Biopharma 2 Ltd Anvendelse af en aromatase-inhibitor i behandlingen af hypogonadisme og relaterede sygdomme
WO2015148549A1 (en) * 2014-03-26 2015-10-01 The Regents Of The University Of California Ultrasensitive androgen receptor bioassay
HUE039037T2 (hu) * 2014-07-07 2018-12-28 Novartis Ag Gyógyászati dózisformák
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CA3055109A1 (en) * 2017-03-08 2018-09-13 Ariad Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
JP7121999B2 (ja) * 2019-09-26 2022-08-19 学校法人九州文化学園 男性性腺機能低下症治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
TW210334B (es) 1990-12-12 1993-08-01 Ciba Geigy Ag
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO2002002113A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
PT1381431E (pt) 2001-04-17 2007-07-03 Ares Trading Sa Inibição da aromatase para melhorar a reprodução assistida.
US7101573B2 (en) 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
AU2003213957A1 (en) * 2002-04-03 2003-10-13 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
EP1937251A2 (en) * 2005-04-25 2008-07-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
WO2009066712A1 (ja) * 2007-11-21 2009-05-28 Kracie Pharma, Ltd. アロマターゼ阻害剤
DK2753312T3 (da) * 2011-09-08 2017-02-13 Mereo Biopharma 2 Ltd Anvendelse af en aromatase-inhibitor i behandlingen af hypogonadisme og relaterede sygdomme

Also Published As

Publication number Publication date
CN103796644B (zh) 2017-05-03
CA2845929C (en) 2018-06-19
SG10201607503WA (en) 2016-10-28
IL231234A (en) 2016-12-29
ES2613667T3 (es) 2017-05-25
MX343902B (es) 2016-11-28
US9295668B2 (en) 2016-03-29
CA2846884A1 (en) 2013-03-14
US20140213622A1 (en) 2014-07-31
BR112014005434A2 (pt) 2017-04-04
MX2014002773A (es) 2014-06-05
ES2613666T3 (es) 2017-05-25
WO2013036563A1 (en) 2013-03-14
LT2753313T (lt) 2017-02-10
US9750724B2 (en) 2017-09-05
CL2014000552A1 (es) 2014-09-12
US9370505B2 (en) 2016-06-21
DK2753312T3 (da) 2017-02-13
BR112014004879B1 (pt) 2020-01-28
AU2012304694B2 (en) 2016-04-07
JP6051467B2 (ja) 2016-12-27
WO2013036562A1 (en) 2013-03-14
CN103781476A (zh) 2014-05-07
HRP20170003T1 (hr) 2017-03-10
SG2014012132A (en) 2014-06-27
KR20140058619A (ko) 2014-05-14
EP2753313B1 (en) 2016-12-14
AU2012304694A1 (en) 2014-03-20
EP2753312B1 (en) 2016-12-14
TW201316987A (zh) 2013-05-01
RU2617510C2 (ru) 2017-04-25
PL2753313T3 (pl) 2017-07-31
KR101872561B1 (ko) 2018-06-28
JP2014528932A (ja) 2014-10-30
CY1118461T1 (el) 2017-07-12
US20160346257A1 (en) 2016-12-01
UY34315A (es) 2013-04-30
CN103781476B (zh) 2016-12-07
PL2753312T3 (pl) 2017-06-30
RU2014113575A (ru) 2015-10-20
PT2753312T (pt) 2017-02-03
HUE031435T2 (en) 2017-07-28
IL231234A0 (en) 2014-04-30
KR20180030254A (ko) 2018-03-21
CA2845929A1 (en) 2013-03-14
LT2753312T (lt) 2017-01-25
AU2012304693A1 (en) 2014-03-13
CA2846884C (en) 2019-04-09
EP2753312A1 (en) 2014-07-16
AU2012304693B2 (en) 2016-03-31
HRP20170002T1 (hr) 2017-02-24
MX360315B (es) 2018-10-29
BR112014004879A2 (pt) 2017-03-14
BR112014005434B1 (pt) 2021-01-05
PE20141584A1 (es) 2014-11-13
PH12014500435A1 (en) 2019-03-22
PT2753313T (pt) 2017-02-02
CN103796644A (zh) 2014-05-14
RU2628808C2 (ru) 2017-08-22
JP6280501B2 (ja) 2018-02-14
HUE031478T2 (hu) 2017-07-28
SI2753313T1 (sl) 2017-04-26
SI2753312T1 (sl) 2017-10-30
TN2014000059A1 (en) 2015-07-01
US10064844B2 (en) 2018-09-04
NZ621476A (en) 2016-02-26
US20160243084A1 (en) 2016-08-25
DK2753313T3 (en) 2017-02-13
CY1118499T1 (el) 2017-07-12
KR20140071358A (ko) 2014-06-11
JP2014526465A (ja) 2014-10-06
AR087790A1 (es) 2014-04-16
IN2014DN01619A (es) 2015-05-15
ZA201401040B (en) 2015-12-23
US20140309267A1 (en) 2014-10-16
RU2014113334A (ru) 2015-10-20
EP2753313A1 (en) 2014-07-16

Similar Documents

Publication Publication Date Title
MX360315B (es) Composiciones farmaceuticas que comprenden un inhibidor de aromatasa.
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
CA2865972C (en) Inhalable dry powders
TN2015000278A1 (en) Autotaxin inhibitors
IL221940A (en) Small anti-infective compounds, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of bacterial infections
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
MX348823B (es) Formulaciones estables de linaclotida.
MX359288B (es) Forma iv del clorhidrato de ivabradina.
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
HK1221653A1 (zh) 用於呼吸递送三种或更多种活性剂的组合物、方法和系统
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
IL223872A (en) Pyrazoloquinoline derivatives and intermediates, process for preparation, use and pharmaceutical preparations and preparations containing them
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
MX2015005762A (es) Producto de comicronizacion que comprende acetato de ulipristal.
WO2013104892A8 (en) Application of high dose compounds via inhalation
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
WO2013170086A3 (en) Formulations for the delivery of active ingredients
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
IL210975A (en) Annapomapungin History, Pharmaceuticals Containing Them and Their Use in Preparing Medicines to Treat Fungal Infections
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
WO2013100718A3 (ko) 라저스트로에미아 오바리폴리아 추출물 또는 이의 분획물을 유효성분으로 포함하는 염증성 질환 또는 천식의 예방 또는 치료용 약학적 조성물
WO2012155226A8 (pt) Processo para a produção de derivados de pyrostegia venusta, derivados de pyrostegia venusta, composições farmacêuticas e seus usos

Legal Events

Date Code Title Description
FG Grant or registration